REGYNERA(dia)TION is an international, multicenter, ambispective observational patient registry of adults with recurrent gynecologic malignancies after prior radiotherapy who are treated or planned for reirradiation and/or total ablative strategies as part of routine clinical care. The registry does not assign treatment. Radiotherapy technique, dose, systemic therapy, surgery, metastasis-directed therapy, imaging, and follow-up are selected by the treating multidisciplinary team according to local standards and patient-specific factors. The registry will collect harmonized retrospective and prospective data on disease characteristics, prior radiotherapy, recurrence pattern, reirradiation or ablative treatment exposure, response, progression, survival, severe treatment-related morbidity, fistula events, and patient-reported outcomes where available.
A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
This trial is no longer recruiting — here are similar active trials
Matched by cancer type/biomarker, currently recruiting.
The primary objective of this study is to measure efficacy of saruparib + physician's choice of ARPI compared with placebo + ARPI in men with metastatic hormone-sensitive prostate cancer (mHSPC) who have previously received docetaxel chemotherapy or a prostate-specific membrane antigen (PSMA)-directed lutetium-177 radioligand therapy with no evidence of disease progression and PSA ≥ 0.2 ng/mL.
This study is open to adults with extensive-stage small cell lung cancer. The purpose of this study is to find out how well people with this type of cancer tolerate taking study medicines called obrixtamig and pumitamig. Another purpose is to check whether the combination study treatment can make tumours shrink. Obrixtamig and pumitamig are being developed to help the immune system fight cancer. Participants are put into 2 groups. One group gets obrixtamig and pumitamig. The other group gets obrixtamig and pumitamig with standard chemotherapy (carboplatin and etoposide). All study treatments are given as infusions into a vein. This study does not have a fixed duration. Participants can receive obrixtamig and pumitamig for up to 2 years if they benefit from treatment and can tolerate it. Participants visit the study site regularly, with some overnight stays required. During this time, doctors regularly check for health problems that could be caused by the study treatment. They also monitor the size of the tumour(s) and take laboratory tests.
The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.
About the trial
TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against Human Epidermal Growth Factor Receptor 2 (HER2), an enzyme-cleavable linker, and a topoisomerase I inhibitor payload, which combine the ability of antibodies to specifically target tumour cells with the highly potent killing activity of drugs with payloads too toxic for systemic administration. This is a Phase 1/Phase 2 study to evaluate the effectiveness, safety, pharmacokinetics (PK) and anti-drug antibody (ADA) of TQB2102 for injection in subjects with HER2-expressing relapsed/metastatic breast cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent świadomie zgadza się na udział i podpisuje formularz zgody.
- •Wiek od 18 do 75 lat.
- •Rak piersi z obecnością cechy HER2, który powrócił lub dał przerzuty.
- •Stan ogólny pozwalający na udział w badaniu (punktacja ECOG 0-1).
- •Szacowany czas przeżycia co najmniej 3 miesiące.
- •Choroba postępująca lub nietolerancja poprzedniego leczenia.
- •Główne narządy pracują prawidłowo.
- •Kobiety w wieku rozrodczym i mężczyźni muszą stosować skuteczną antykoncepcję podczas badania i 6 miesięcy po jego zakończeniu.
✗ Disqualifies
- •Inny nowotwór zdiagnozowany lub leczony w ciągu ostatnich 3 lat.
- •Nieustępujące poważne skutki uboczne poprzedniego leczenia (poza wypadaniem włosów).
- •Duża operacja, biopsja nacięciowa lub poważny uraz w ciągu ostatnich 28 dni.
- •Nieleczone rany lub złamania.
- •Przebyta choroba płuc wymagająca leczenia sterydami lub podejrzenie takiej choroby.
- •Zakrzepica żył lub tętnic.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- July 8, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (20)
Anhui Pronvincial Cancer Hospital
Hefei, China
Lu'an People's Hospital
Lu'an, China
Cancer Hospital Chinese Academy of Medical Science
Beijing, China
Chongqing University Cancer Hospital
Chongqing, China
Sun Yat-Sen University Cancer Center
Guangzhou, China
Jiangmen Central Hospital
Jiangmen, China
Guangxi Medical University Cancer Hospital
Nanning, China
Harbin Medical University Cancer Hospital
Harbin, China
Hunan Cancer Hospital
Changsha, China
Ganzhou People's Hospital
Ganzhou, China
Jilin Cancer Hospital
Changchun, China
Liaoning Cancer Hospital & Institute
Shenyang, China
The First Hospital of China Medical University
Shenyang, China
Cancer Hospital Affiliated to Shandong First Medical University
Jinan, China
Linyi Cancer Hospital
Linyi, China
The First Affiliated Hospital of Xi'an Jiaotong University School of Medicine
Xi'an, China
Shanxi Cancer Hospital
Taiyuan, China
Suining Central Hospital
Suining, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China
Zhejiang Cancer Hospital
Hangzhou, China
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.